Cargando…

Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic

The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Damasceno Junior, Elmar, Barbosa, Raquel de Melo, da Silva, Rita de Cássia Dantas, Costa, Felipe dos Santos, da Silva, Djalma Ribeiro, Viseras, César, Perioli, Luana, Fernandes, Nedja Suely
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966939/
https://www.ncbi.nlm.nih.gov/pubmed/36839834
http://dx.doi.org/10.3390/pharmaceutics15020512
_version_ 1784897141225816064
author Damasceno Junior, Elmar
Barbosa, Raquel de Melo
da Silva, Rita de Cássia Dantas
Costa, Felipe dos Santos
da Silva, Djalma Ribeiro
Viseras, César
Perioli, Luana
Fernandes, Nedja Suely
author_facet Damasceno Junior, Elmar
Barbosa, Raquel de Melo
da Silva, Rita de Cássia Dantas
Costa, Felipe dos Santos
da Silva, Djalma Ribeiro
Viseras, César
Perioli, Luana
Fernandes, Nedja Suely
author_sort Damasceno Junior, Elmar
collection PubMed
description The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability.
format Online
Article
Text
id pubmed-9966939
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99669392023-02-26 Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic Damasceno Junior, Elmar Barbosa, Raquel de Melo da Silva, Rita de Cássia Dantas Costa, Felipe dos Santos da Silva, Djalma Ribeiro Viseras, César Perioli, Luana Fernandes, Nedja Suely Pharmaceutics Article The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2(4) factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability. MDPI 2023-02-03 /pmc/articles/PMC9966939/ /pubmed/36839834 http://dx.doi.org/10.3390/pharmaceutics15020512 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Damasceno Junior, Elmar
Barbosa, Raquel de Melo
da Silva, Rita de Cássia Dantas
Costa, Felipe dos Santos
da Silva, Djalma Ribeiro
Viseras, César
Perioli, Luana
Fernandes, Nedja Suely
Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title_full Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title_fullStr Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title_full_unstemmed Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title_short Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic
title_sort montmorillonite–rifampicin nanohybrid for ph-responsive release of the tuberculostatic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966939/
https://www.ncbi.nlm.nih.gov/pubmed/36839834
http://dx.doi.org/10.3390/pharmaceutics15020512
work_keys_str_mv AT damascenojuniorelmar montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT barbosaraqueldemelo montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT dasilvaritadecassiadantas montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT costafelipedossantos montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT dasilvadjalmaribeiro montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT viserascesar montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT perioliluana montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic
AT fernandesnedjasuely montmorilloniterifampicinnanohybridforphresponsivereleaseofthetuberculostatic